Free Trial

Sana Biotechnology (NASDAQ:SANA) Given New $11.00 Price Target at Citigroup

Sana Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Citigroup lowered its price target for Sana Biotechnology to $11 while maintaining a Buy rating; the target implies 480.47% upside from the previous close.
  • Analyst views are mixed, but the consensus rating is Moderate Buy with an average target price of $9.83.
  • Sana shares traded at $1.90 on Monday, near their 12-month low of $1.86. The company reported a quarterly loss of $0.14 per share, slightly better than analysts’ $0.15 loss estimate.
  • MarketBeat previews the top five stocks to own by December 1st.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) had its price target dropped by analysts at Citigroup to $11.00 in a report released on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Citigroup's price target would indicate a potential upside of 480.47% from the stock's previous close.

SANA has been the topic of a number of other reports. Weiss Ratings downgraded shares of Sana Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday. Bank of America reduced their price objective on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Friday, August 14th. Wall Street Zen raised shares of Sana Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. Finally, TD Cowen raised shares of Sana Biotechnology to a "strong-buy" rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology has a consensus rating of "Moderate Buy" and a consensus target price of $9.83.

View Our Latest Report on Sana Biotechnology

Sana Biotechnology Stock Performance

SANA traded down $0.12 during midday trading on Monday, hitting $1.90. The company had a trading volume of 2,464,938 shares, compared to its average volume of 3,167,266. The firm's 50-day simple moving average is $2.72 and its 200-day simple moving average is $3.29. The company has a market capitalization of $567.81 million, a PE ratio of -3.58 and a beta of 2.30. Sana Biotechnology has a twelve month low of $1.86 and a twelve month high of $5.49.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. As a group, sell-side analysts anticipate that Sana Biotechnology will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds have recently made changes to their positions in the stock. Palumbo Wealth Management LLC boosted its holdings in shares of Sana Biotechnology by 39.6% during the third quarter. Palumbo Wealth Management LLC now owns 83,462 shares of the company's stock worth $243,000 after purchasing an additional 23,689 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Sana Biotechnology in the 3rd quarter valued at approximately $45,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Sana Biotechnology by 23.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,622 shares of the company's stock worth $159,000 after acquiring an additional 10,332 shares during the period. T3 Companies LLC increased its position in Sana Biotechnology by 162.8% during the third quarter. T3 Companies LLC now owns 29,700 shares of the company's stock valued at $87,000 after acquiring an additional 18,400 shares during the last quarter. Finally, Abel Hall LLC purchased a new stake in Sana Biotechnology during the third quarter valued at approximately $35,000. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

(Get Free Report)

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company's research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.

Further Reading

Analyst Recommendations for Sana Biotechnology (NASDAQ:SANA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sana Biotechnology Right Now?

Before you consider Sana Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.

While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines